Signature

9-24-03

PTO/SB/21 (08-03) Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ne Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/643,824 **TRANSMITTAL** Filing Date **FORM** First Named Inventor Nelson, Ernest Peter Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Technology Center (TC) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Terminal Disclaimer Identify below): Extension of Time Request Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Kenneth A. Keeling Keeling Hudson, L.L.C. Individual name Signature Date CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. ER 216 164 121 US Typed or printed name Kenneth A. Keeling

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ernest Peter Nelson

Serial No.: 10/643,824 Group No.:

Filed:

For: LEG USCER, LYMPHOEDEMA AND DVT VIBRATORY TREATMENT DEVICE

Examiner:

Commissioner for Patents Washington DC 20231

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- 1. Preliminary Statements
- 2. Forms PTO 1449 (now PTO/SB/08A and 08B)
- 3. Copies of Listed Information Items Accompanying This Statement
- 4. Concise Explanation of English Language Listed Information Items
- 5. Identification of Person(s) Making This Information Disclosure Statement

Section 1. Preliminary Statements

Applicant(s) submits herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as attached thereto are being deposited with the United States Postal Service on the date listed below, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number <u>ER 216 164 121 US</u>, addressed to the: Commissioner for Patents, Washington, DC 20231.

9-23-03

Date

Kenneth A. Keeling Registration No. 31,842 cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. PTO 1449 (Now Forms PTO/SB/08A and 08B)

PTO Form 1449 is attached hereto.

Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Section 4. Concise Explanation of English Language Listed Information Items

- 1. "The Use of Cycloidal Vibrations Therapy on Blood and Lymph Circulation and on Wound Healing," presented at the VII International Congress of Lymphology, Firenze, Italy on October 28 to November 2, 1979 by Lievens, Leduc and Dewald Suggests that some aspects of wound healing in test mice were improved by a regime of cycloidal vibrations.
- 2. "The Effect of cycloid Vibration on Leg Blood Flow and Ulcer Pain," presented to the Section of Dermatology of the Royal Society of Medicine in 1978 by Pickup, Alexander, and Gosling Discloses that while vibration was recognized to dramatically reduce pain from leg ulcers, only a slight improvement in healing was noticed.
- 3. "The Effects of Vibration Upon Blood-Viscosity and Red-Cell Mobility: A Study In Vivo and In-Vitro," by Ramcharan, Shoja, Piggott and Taylor, published in Biorheology Vol. 19, pages 341 to 352 in 1982

Presents studies of three dimensional, or "cycloid" vibration showing that vibration of either human or rabbit blood in vitro has no effect on blood-viscosity at any sheer rate, on red cell mobility, on zeta-potential or on yield stress. Whole-body vibration produced no significant effect on rheology at rates of shear above 2 s-l, but low-shear viscosity (<1 s-l Shear rate) became more Newtonian after vibration, with a significant reduction in yield stress from 5.71 +/-0.14 mNm-2 to 3.54 +/- 0.32 mNm-2.

4. "The Effects of Vibration on Skin Blood Flow," by Ryan and Salter, published in Biblotheca Anatomica, No. 16, pages 180 – 184 in 1977 and presented at the 9th European Conference of Microcirculation in Antwerp, Belgium in 1976

Presents interpretation on effect of vibration. Concludes that the effect of vibration is primarily to disperse tissue fluid, which is therapeutically useful for conditions where stiffness, pain or swelling are directly related to an excess of fluid in the tissues.

5. "Improvement of Blood Flow in Ischaemic Limbs by the Use of Cycloid Vibration Therapy by Askari and Rozov (No publication date is available)

Presents a trial study of applying cycloid vibration to patients with cases of severe occlusive peripheral vascular disease.

Section 5. Identification of Person(s) Making This Information Disclosure Statement

The po	erson making tl	nis statement is:					
(a)	☐ the invent	or(s) who signs below.					
(b)	☐ an individ	an individual associated with the filing and prosecution of this application.					
(c)	■ the practitioner who signs below on the basis of the information:						
		supplied by the inventor(s). supplied by an individual associated with the filing and prosecution of this application (37 CFR 1.56(c)) in the practitioner's file.					

Respectfully submitted,

Kenneth A. Keeling Registration No. 31,842 James E. Hudson III Registration No. 41,081

September 2**3**, 2003 Keeling Hudson L.L.C. 901 North Post Oak Road Houston, Texas 77024 713-680-1447 713-680-8567 (Fax)

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Uni	Under The Paperwork Reduction Act of 1995, no persons are			C mpl t if Kn wn		
Substitute for form 1449/PTO				Applicati n Number	10/643,824	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			CLOSURE	Filing Date		
			PPLICANT	First Named Inventor	Ernest Peter Nelson	
				Art Unit		
			ecessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	LIEVENS, LEDUC, DEWALD, "The Use of Cycloidal Vibrations Therapy on Blood and Lymph Circulation and	
		on Wound Healing," VII International Congress of Lymphology, 10/28/1979 to 11/2/1979, Firenze, Italy	
	-	PICKUP, ALEXANDER, GOSLING, "The Effect of cycloid Vibration on Leg Blood Flow and Ulcer Pain,"	
		Section of Dermatology of the Royal Society of Medicine, 1978.	
		RAMCHARAN, SHOJA, PIGGOTT, TAYLOR, "The Effects of Vibration Upon Blood-Viscosity and Red-Cell	
		Mobility: A Study In Vivo and In-Vitro," Biorheology, 1982, Vol 19, Pergamon Press Ltd., USA.	
	-	RYAN, SALTER, "The Effects of Vibration on Skin and Blood Flow," Biblotheca Anatomica, 1977, Vol. 16	
		S. Karger, Basel, Switzerland	
	/	ASKARI, ROZOV, "Improvement of Blood Flow in Ischaemic Limbs by the Use of Cycloid Therapy," Israel,	
		Other publication information not available.	

Examiner	1	Date	002-02
Signature		Considered	905-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.